Nycomed's Omniscan approved in Japan

Article

Hafslund Nycomed's Omniscan MRI contrast agent has been certifiedfor marketing in Japan, the Oslo, Norway, company reported thismonth. Nycomed said that Omniscan will be launched by DaiichiPharmaceutical, Nycomed's Japanese licensee, as soon as

Hafslund Nycomed's Omniscan MRI contrast agent has been certified

for marketing in Japan, the Oslo, Norway, company reported this

month. Nycomed said that Omniscan will be launched by Daiichi

Pharmaceutical, Nycomed's Japanese licensee, as soon as final

price approval is granted by Japanese authorities. Nycomed added

that it has submitted an application for marketing approval in

Japan for Visipaque, its third-generation x-ray contrast agent.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.